Furthermore, gene therapy (98), TAM therapy (99), and recombinant cytokines such as IL-10 (51), interferon transforming growth factor-β (TGF-β) (100), colony- stimulating factor 1 receptor (CSF1R) (62) have been used in GBM clinical trials and have shown some therapeutic potential in specific glioma populations. This evidence concerns the gene CSF1R and central nervous system cancer.